Navigation Links
New Platform for Regulating Expression of Therapeutic Genes Unveiled

A new platform for regulating the expression of therapeutic genes, which will have major implications for gene and cell therapy, was presented today at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

Carefully regulating gene expression is crucial to the success of gene and cell therapy. For many applications, gene transfer is being employed to engineer cells for therapeutic factor production, expansion, selection of a desired cell type and even fail-safe suicide. These applications often require precise regulation in order to ensure gene expression in the correct tissue and prevent it in unwanted cell types.

Now, a team of scientists led by Dr. Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) in Milan have developed a new platform. Dr. Naldini and colleagues provided a striking demonstration that their new design can enable delivered genes to become highly responsive to a cells identity. This is particularly relevant for the emerging field of stem cell gene therapy, in which genes are delivered into a cell that can give rise to many distinct cell types.

To achieve their goal, the TIGET scientists came up with a strategy to take advantage of a recently discovered network of gene regulation mediated by small RNA molecules, known as microRNA.

MicroRNAs downregulate the expression of specific genes in cells where the gene is not needed, and thereby have an important influence over the identity of the cell. More than 350 mammalian microRNAs have been identified, with many being present only in some specific tissues and cell types.

Dr. Naldinis group showed that the addition of microRNA binding sites into their gene delivery vectors results in gene regulation dictated by the cells own cognate microRNA. Simply put, they could engineer their gene to be turned off in cells where the microRNA is present. As a proof-of-principle, the resea rchers used a lentiviral vector to introduce a gene encoding a fluorescent protein into human embryonic stem cells. Their gene contained target sites for a microRNA specific of neuronal cells. While undifferentiated, the embryonic stem cells expressed high levels of the fluorescent gene, however, as soon as the cells turned into neurons, the engineered gene was turned off in response to the presence of the microRNA in the neurons. So versatile is their approach, that they could even demonstrate the reverse. By changing the microRNA binding site in their vector to one recognized by an embryonic stem cell-specific microRNA, their vector was kept off in immature embryonic stem cells, but began to express itself as the cell turned into more defined tissues. This new platform now provides a means for scientists to achieve highly tailored gene expression patterns when delivering recombinant genetic material into cells.

We had been looking for ways to regulate transgenes better, when it hit us, nature had already solved the problem for us, says Dr. Brian Brown, one of the studies authors. Now, we can utilize a cells own regulatory network to control a gene we introduce.

Dr. Naldinis group has already begun to successfully exploit microRNA regulation for achieving stable long-term correction of hemophilia in the mouse model and for improving the safety of hematopoietic stem cell gene therapy.

The American Society of Gene Therapy is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene and related cell and nucleic acid therapies and the promotion of professional and public education in the field.


'"/>




Related medicine news :

1. Lovers Latest Hang Outs – Railway Platform
2. Substance P May Pre-empt VIP in Regulating Temperature
3. Controlled Gene Expressions Can Cure Many Diseases
4. Genetic Expressions Can Influence The Process Of Aging
5. Non-Coding RNA Vital For Gene Activation And Protein Expression
6. Protein Expression to Serve as Marker for Head and Neck Cancer
7. Innocent Expression of Compassion, Children Draw For HIV kids
8. New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders
9. Facial Expressions are Inherited: Study
10. Telomerase Expression Linked To Body Mass
11. How Blood Flow Dictates Gene Expression
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2016)... ... February 13, 2016 , ... ... Data Management Solution Providers list for its expertise in eClinical Solutions. DDi has ... to serve the technology needs of global clients. DDi provides smarter technology for ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted over 250 members of South Florida’s philanthropic community at its 10th anniversary ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology: